These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 7328996)

  • 41. [Retreatment of pulmonary tuberculosis--duration of chemotherapy].
    Wada M; Seita A; Mori T; Ogata H; Sugie T; Sugita H
    Kekkaku; 1993 Jul; 68(7):469-78. PubMed ID: 8361115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Studies of serum rifampicin concentrations].
    Takamoto M; Shinoda A; Kondou H; Nagano H; Kutsukake F; Mochizuki K; Taga Y; Yasutake T; Takano T; Hiro Y
    Kekkaku; 1986 Aug; 61(8):425-33. PubMed ID: 3784240
    [No Abstract]   [Full Text] [Related]  

  • 43. [New information on the metabolism of isoniazide and rifampicin. Their therapeutical consequences (author's transl)].
    Sauvaget J; Sainte-Laudy J; Canavate A
    Poumon Coeur; 1979; 35(5):287-92. PubMed ID: 537976
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effectiveness of chemotherapy of chronic forms of pulmonary tuberculosis under hospital conditions].
    Kolesnikov VV; Mikhaĭlov VI; Matviiakina TS
    Probl Tuberk; 1980 Mar; (3):41-4. PubMed ID: 7393892
    [No Abstract]   [Full Text] [Related]  

  • 45. Drug resistance in tuberculosis in Delhi: a 2 year profile (2001--2002).
    Negi SS; Gupta S; Lal S
    J Commun Dis; 2003 Jun; 35(2):74-81. PubMed ID: 15562952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment of multi resistant pulmonary tuberculosis with rifampin (author's transl)].
    Mena G; Carrasco E; Velasco J; Valenzuela P; Busel I
    Rev Med Chil; 1974 Oct; 102(10):798-803. PubMed ID: 4458021
    [No Abstract]   [Full Text] [Related]  

  • 47. [Comparative studies on therapeutic effect of rifampicin and isoniazid on experimental mouse tuberculosis (author's transl)].
    Kondo E; Kanai K
    Kekkaku; 1978 Apr; 53(4):261-4. PubMed ID: 661058
    [No Abstract]   [Full Text] [Related]  

  • 48. Anti-tuberculous initial drug resistance of Mycobacterium tuberculosis in Kenya: a ten-year review.
    Githui WA; Kwamanga D; Chakaya JM; Karimi FG; Waiyaki PG
    East Afr Med J; 1993 Oct; 70(10):609-12. PubMed ID: 8187653
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
    Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Relationship between rate of inactivation of isoniazid and changes in transaminase levels during combined isoniazid-rifampicin therapy (author's transl)].
    Sehm G; Urbanczik R
    Prax Pneumol; 1974 Nov; 28(11):613-5. PubMed ID: 4453525
    [No Abstract]   [Full Text] [Related]  

  • 51. Tuberculosis of the breast.
    Göksoy E; Düren M; Durgun V; Uygun N
    Eur J Surg; 1995 Jul; 161(7):471-3. PubMed ID: 7488659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
    Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Primary resistance to isoniazid (author's transl)].
    Jungbluth H; Bürger B
    Prax Klin Pneumol; 1979 Nov; 33(11):1106-8. PubMed ID: 523420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Use of lymphotropic therapy in the multimodality treatment of patients with pulmonary tuberculosis and comorbidity].
    Ubaĭdullaev AM; Belotserkovets VG
    Probl Tuberk Bolezn Legk; 2004; (12):50-2. PubMed ID: 15719669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Results of treatment by a combination of thiocarlide and isoniazid in previously untreated pulmonary tuberculosis].
    Aksüğür H; Gülbaran R; Cakirca R
    Poumon Coeur; 1967; 23(6):729-38. PubMed ID: 6070030
    [No Abstract]   [Full Text] [Related]  

  • 56. [Combined chemotherapy of patients with tuberculosis - new regimens and dosage forms].
    Sokolova GB; Koriakin VA; Khalbaeva IV; Elistratova NA; Ziia AV
    Probl Tuberk; 1993; (5):21-3. PubMed ID: 8295879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effectiveness of chemotherapy in patients with primary distructive tuberculosis].
    Novikova NA
    Probl Tuberk; 1967; 45(5):21-6. PubMed ID: 5617940
    [No Abstract]   [Full Text] [Related]  

  • 58. [Case report on the treatment of bone tuberculosis with rifampicin (Rimactan)].
    Stäubli C
    Schweiz Med Wochenschr; 1970 Oct; 100(43):1856-8. PubMed ID: 5524930
    [No Abstract]   [Full Text] [Related]  

  • 59. [Active fraction of isonicotinic acid hydrazide in the blood of tuberculosis patients during its combined use with PAS].
    Dudchik GKh; Bilyk MA
    Vrach Delo; 1981 Feb; (2):77-8. PubMed ID: 7222619
    [No Abstract]   [Full Text] [Related]  

  • 60. [The present situation, treatment and prognosis of drug-resistant pulmonary tuberculosis. Cooperative Study Unit of Chemotherapy of Tuberculosis of the National Sanitoria in Japan].
    Sato K; Nagai H; Kurashima A; Mori M; Katayama T
    Kekkaku; 1995 Oct; 70(10):585-9. PubMed ID: 8523851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.